secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001171843-25-002741
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose TUSCANY trial: TUS+VEN+AZA triplet shows CRs, MRD negativity in high-risk AML
--------------------------------------------------------------------------------

- Four patients at 40 mg TUS+VEN+AZA: three achieved CR/CRi and MRD-negative, including a TP53-mutated/CK AML patient.
- Three patients at 80 mg TUS+VEN+AZA: all had blast reductions meeting CR/CRi criteria in Cycle 1; no DLTs reported.
- No dose-limiting toxicities across both cohorts; safety profile favorable for the triplet combination.
- Enrollment target of 18–24 patients by mid-late 2025; additional data releases expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002741/0001171843-25-002741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325002741/f8k_050225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer